Eli Lilly | Srodki Pieniężne I Ekwiwalent



Cash And Equivalent Zmiana Data
AbbVie USD 5.52B 1.73B 2024-12
Abbott USD 7.62B 58M 2024-12
ALKERMES USD 291.15M 636.63M 2024-12
Amgen USD 11.97B 2.96B 2024-12
AstraZeneca USD 5.49B 691M 2024-12
Baxter International USD 1.76B 344M 2024-12
Biogen USD 2.38B 675.8M 2024-12
Bristol-Myers Squibb USD 10.35B 2.46B 2024-12
Drreddys Laboratories INR 1.1B 743M 2024-12
Eli Lilly USD 3.27B 100.6M 2024-12
Gilead Sciences USD 9.99B 4.95B 2024-12
GlaxoSmithKline GBP 3.87B 678M 2024-12
Glaxosmithkline GBP 3.87B 678M 2024-12
Indivior 288M 14M 2024-09
J&J USD 6.12B 1.28B 2024-12
Medtronic USD 1.24B 154M 2025-01
Merck USD 13.24B 1.35B 2024-12
Neurocrine Biosciences USD 233M 116.1M 2024-12
Novartis USD 8.87B 4.74B 2024-12
Novartis USD 11.46B 2.15B 2024-12
Perrigo USD 558.8M 904.7M 2024-12
Pfizer USD 1.04B 49M 2024-12
Prestige Brands USD 50.87M 666K 2024-12
Regeneron Pharmaceuticals USD 17.91B 15.9B 2024-12
Roche Holding CHF 6.98B 2.15B 2024-12
Sanofi 6.8B 1.92B 2024-06
Sanofi 6.8B 1.92B 2024-06
United Therapeutics USD 1.7B 143.3M 2024-12
Zoetis USD 1.98B 275M 2024-12



Eli Lilly Srodki Pieniężne I Ekwiwalent - Aktualne wartości, dane historyczne, prognozy, statystyki, wykresy i kalendarz ekonomiczny - Mar 2025.